WO2007051957A1 - Préparation et méthode - Google Patents

Préparation et méthode Download PDF

Info

Publication number
WO2007051957A1
WO2007051957A1 PCT/GB2006/002165 GB2006002165W WO2007051957A1 WO 2007051957 A1 WO2007051957 A1 WO 2007051957A1 GB 2006002165 W GB2006002165 W GB 2006002165W WO 2007051957 A1 WO2007051957 A1 WO 2007051957A1
Authority
WO
WIPO (PCT)
Prior art keywords
sterilising
composition
composition according
peracetic acid
solution
Prior art date
Application number
PCT/GB2006/002165
Other languages
English (en)
Inventor
Keith Martin Macgregor
Original Assignee
Ebiox Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ebiox Limited filed Critical Ebiox Limited
Priority to EP06744206A priority Critical patent/EP1945274A1/fr
Publication of WO2007051957A1 publication Critical patent/WO2007051957A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A61L2/186—Peroxide solutions
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/16—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group; Thio analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20—Targets to be treated
    • A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps

Definitions

  • the present invention relates to a composition and method for use in sterilising applications, particularly in the field of sterilising medical equipment.
  • An alternative sterilising method is immersion of equipment in a sterilising composition.
  • Such compositions are well known. However, they are often time-consuming to prepare, require long immersion periods, are unstable, or are of inadequate efficacy.
  • a sterilising composition comprising a source of peracetic acid, at least one anionic surfactant and at least one amphoteric surfactant .
  • the sterilising solution is provided in concentrated form which may be diluted with water to form a sterilising solution.
  • the source of peracetic acid may comprise any suitable source.
  • it comprises a peracetic acid precursor, and an activator.
  • the peracetic acid precursor comprises an organic compound having at least one acetyl residue, preferably more than one acetyl residue.
  • the peracetic acid precursor compound preferably comprises an amine or alcohol having an acetyl group appended thereto i.e., preferably the peracetic acid precursor compound comprises an organic compound in which an acetyl group is bonded to a nitrogen or oxygen atom.
  • the peracetic acid precursor compound comprises an amine, preferably an amine having an acetyl residue bonded thereto.
  • the peracetic acid precursor compound may comprise more than one amine group. At least one of said amine groups has an acetyl group appended thereto. Preferably there are at least two amine groups, each of which has an acetyl group appended thereto.
  • the peracetic acid precursor compound comprises an organic compound having an amine group, said amine group having at least two acetyl groups bonded to a single nitrogen atom.
  • the organic compound comprises a diamine.
  • each nitrogen atom of said diamine has two acetyl groups appended thereto.
  • the peracetic acid precursor compound comprises tetraacetylethylene diamine.
  • the peracetic acid precursor compound may be selected from the list comprising acetylsalicyclic acid, acetic acid, tetraacetyl glycouracil, pentaacetylglucose, N,N-diacetylaniline, N, N- diacetyl-p-toluidine; 1, 3-diacylated hydantoins, N- acylated cyclic hydrazides, and acylated triazones or urazoles .
  • Suitable activators for use in the present invention include any means which may bring about the conversion of the peracetic acid precursor to peracetic acid.
  • the activator comprises an oxidising agent.
  • Said oxidising agent is able to oxidise the acetyl groups on the peracetic acid precursor compound to form peracetic acid.
  • Suitable oxidising agents for use in the invention include alkali metal peroxides; hydrogen peroxide; organic peroxides, for example, urea peroxide, perbenzoic acid and peroxycarboxylic acids such as mono or diperoxyphthalic acid, diperoxy-azelaic acid, 2-octyldiperoxysuccinic acid, diperoxydodecanedicarboxylic acid, imidoperoxycarboxylic acid, the salts thereof, phlalimidoperhexanoic acid (PAP) ; and inorganic persalts, such as the alkali metal perborates, percarbonates , perphosphates , persilicates and persulfates .
  • PAP phlalimidoperhexanoic acid
  • the activator comprises a perborate compound.
  • the activator comprises sodium perborate, especially as a mo ⁇ ohydrate .
  • a preferred source of peracetic acid is tetraacetylethyl diamine as a peracetic acid precursor and sodium perborate monohydrate as an activator.
  • any following definition which refers to the amount of a component present in a composition of the present invention more than one of any such components may be present and the reference is made to the total amounts of all such components present in the composition.
  • composition preferably comprises at least 20 wt% of the source of peracetic acid, more preferably at least
  • the composition preferably comprises up to 90 wt% of the source of peracetic acid, more preferably up to 80 wt%, more preferably up to 75 wt%, most preferably up to 70 wt%.
  • the above percentages refer to the total amount of the source of peracetic acid, including the peracetic acid precursor and the activator.
  • the composition comprises at least 5 wt% peracetic acid precursor, more preferably at least 10 wt%, most preferably at least 12 wt%.
  • the composition comprises up to 40 wt% peracetic acid precursor, more preferably up to 30 wt%, most preferably up to 20 wt%.
  • the composition comprises at least 10 wt% activator, more preferably at least 20 wt%, more preferably at least 30 wt%, and most preferably at least
  • the composition comprises up to 70 wt% activator, more preferably up to 60 wt%, more preferably up to 55 wt%, and most preferably up to 50 wt%.
  • the composition comprises at least 0.1 wt% anionic surfactant, more preferably at least 0.5 wt%, more preferably at least 1 wt%, most preferably at least 1.5 wt%.
  • the composition comprises up to 10 wt% anionic surfactant, more preferably up to 8 wt%, most preferably up to 5 wt% anionic surfactant .
  • Suitable anionic surfactants include sodium and potassium salts of fatty carboxylic acids, sulfonates, alkyl sulfates, alkylether carboxylic acids and their salts, sulfosuccinates, alkoxylated alkyl sulfates, torides, alkylphosphates and sarcosocides .
  • alkyl sulfates and alkyl polyalkoxylated sulfates may be produced by the sulfonation of higher C 8 - C 20 fatty alcohols .
  • alkyl sulfate surfactants are those of formula:
  • R is a C 8 -C 20 hydrocarbon group and M is a water- solubilising cation.
  • R is Ci 0 -C 16 alkyl, for example Ci 2 -C 14
  • M is an alkali metal such as lithium, sodium or potassium.
  • alkoxylated alkyl sulfates are ethoxylated alkyl sulfates of the formula: RO(C 2 H 4 O) n SO 3 -M +
  • R is a C 8 -C 20 alkyl group, preferably C 10 -Ci 8 such as a Ci 2 -Ci 6
  • n is at least 1, for example from 1 to 20, preferably 1 to 15, especially 1 to 6
  • M is a salt- forming cation such as lithium, sodium, potassium, ammonium, alkylammonium or alkanolammonium.
  • alkyl sulfates and alkyl ether sulfates may be used in the form of mixtures comprising varying alkyl chain lengths and, if present, varying degrees of alkoxylation.
  • anionic surfactants which may be employed are salts of C 8 -Ci 8 fatty acids, especially the sodium or potassium salts, and alkyl, for example C 8 -Ci 8 , benzene sulfonates .
  • the anionic surfactant comprises a sulfonate, more preferably an alkylbenzene sulfonate, most preferably a linear alkylbenzene sulfonate.
  • said linear alkylbenzene sulfonate has between 8 and 18 carbon atoms.
  • a suitable linear alkylbenzene sulfonate is commercially available under the trade mark Nansa HS80/S.
  • a composition of the present invention comprises at least 0.1 wt% amphoteric surfactant, more preferably at least 0.5 wt%, more preferably at least 1 wt%, most preferably at least 1.5 wt%.
  • the composition comprises up to 10 wt% amphoteric surfactant, more preferably up to 8 wt%, most preferably up to 5 wt% amphoteric surfactant.
  • amphoteric surfactants include amphoteric betaine surfactant compounds having the following general formula:
  • R is a hydrophobic group which is an alkyl group containing from 8 to 20 carbon atoms ; each R ⁇ is an alkyl group independently containing from 1 to 3 carbon atoms; and R2 is an alkylene group containing from 1 to 6 carbon atoms .
  • exemplary useful amphoteric surfactants include those selected from alkylampho (mono) - and (di) - acetates, alkylampho (mono) - and (di) -propionates, and aminopropionates .
  • alkylampho (mono) acetates include those according to the general structure:
  • R represents a R represents a C8 to C24 alkyl moiety.
  • R represents a C8 to C24 alkyl moiety.
  • Suitable alkylampho (mono) propionates include those according to the according to the general structure :
  • R represents a R represents a C8 to C24 alkyl moiety.
  • Suitable alkylampho (di) propionates include those according to either of the general structures :
  • R represents a R represents a C8 to C24 alkyl moiety.
  • Suitable aminopropionates include those according to the following general structure : CH 2 CH 2 COO 0 RNH 9 CH 2 CH 2 COOH
  • R represents a R represents a C8 to C24 moiety.
  • R represents a C8- C24 alkyl group and desirably is a C10-C16 alkyl group, especially derived from soy or coconut the latter of which typically provides a mixture of C8-10, C12, C14 and C16 alkyl groups .
  • amphoteric surfactant comprises beta- alanine,N- (carboxyethyl) -N-dodecyl monosodium salt.
  • the mass ratio of anionic surfactant to amphoteric surfactant is preferably in the range of from 1:3 to 3:1.
  • the anionic surfactant is present in a mass excess compared with the amphoteric surfactant.
  • the ratio of anionic surfactant to amphoteric surfactant is between 1:1 and 2:1, most preferably it is about 1.5:1.
  • composition of the present invention further comprises a weak acid, preferably an organic acid.
  • the composition of the present invention comprises a carboxylic acid having from 1 to 5 carbon atoms, and between 1 and 4 carboxylic acid residues.
  • the composition of the present invention comprises citric acid.
  • the composition comprises said weak acid in an amount of at least 5 wt%, more preferably at least 10 wt%, most preferably at least 15 wt%.
  • the composition comprises up to 50 wt% weak acid, more preferably up to 40 wt%, most preferably up to 30 wt%.
  • composition of the present invention further comprises one or more solubilising agents.
  • Suitable solubilising agents include common salts of group 1 and group 2 metals .
  • solubilising agents are selected from the group consisting of sulfates, nitrates, carbonates and bicarbonates .
  • the composition of the present invention comprises sodium bicarbonate and sodium sulphate as solubilising agents .
  • composition of the present invention further comprises a sequestrant.
  • sequestrants include citrate, succinate, malonate, carboxymethyl succinate, carboxylate, polycarboxylate and polyacetyl carboxylate, as the salts of group 1 or group 2 metals, or as free acids .
  • Examples include the sodium, potassium and lithium salts of oxydisuccinic acid, mellitic acid, benzene polycarboxylie acids, Ci O -C 2 2 fatty acids and citric acid.
  • Preferred sequestering agents are organic phosphonate type sequestering agents such as those sold by Monsanto under the trade mark Dequest, and alkylhydroxy phosphonates .
  • a preferred sequestrant is phosphonic acid Deguest.
  • the sequestering agent is preferably present in an amount of less than 1 wt%.
  • composition of the present invention further comprises an indicator, most preferably a visual indicator.
  • said indicator changes colour in the pH range of between 3 and 10, preferably of between 6 and 8.
  • Suitable indicators include phenol red, brilliant yellow, cresol red, neutral red, paranitrophenol, and bromothymol blue.
  • a preferred indicator is Phenol Red.
  • the indicator is preferably such that a colour change occurs when the useful life of a solution prepared from the composition of the present invention has expired.
  • composition of the present invention is preferably provided as a powder.
  • the above weight percentages of components present in the composition refer to this dry powder .
  • composition is diluted to form a solution prior to use .
  • the composition of the present invention has a solubility at 40 0 C in water of at least 5g per litre, more preferably at least 1Og per litre, most preferably at least 15g per litre. Said solubilities are measured by stirring the composition in water at 40° C for a period of 5 minutes .
  • the composition of the present invention forms an aqueous solution having pH of between 4 and 12, more preferably of between 2 and 11, more preferably between 5 and 11, preferably between 6 and 10, and most preferably between 7 and 9.
  • the composition of the present invention forms a solution having an alkaline pH, preferably least 7.5.
  • the composition of the present invention provides a solution having an initial pH of about 8. The pH of the solution may vary over time, preferably the pH does not fall below 6 during the first 24 hours .
  • the composition of the present invention forms a solution having a peracetic acid content of at least 900 ppm, after 5 minutes. More preferably at least 1,000, preferably at least 1,200 ppm, most preferably at least 1,400 ppm, after 5 minutes.
  • composition of the present invention provides a solution which after 4 hours has a peracetic acid concentration of at least 700 ppm, more preferably at least 800 ppm, most preferably at least 1,000 ppm.
  • the composition of the present invention forms a solution which maintains a peracetic acid concentration of at least 700 ppm, more preferably at least 800 ppm, preferably at least 900 ppm, most preferably at least 1,000 ppm for at least 4 hours, more preferably at least 6 hours, more preferably at least 8 hours, and most preferably at least 10 hours.
  • the present invention provides a composition which dissolves to form a solution having a peracetic acid concentration of at least 1,400 ppm within 5 minutes, and which also maintains a peracetic acid concentration of at least 1,000 ppm over a period of 10 hours.
  • a concentrate composition comprising:
  • amphoteric surfactant - 1 to 3.5 wt% amphoteric surfactant .
  • a method of preparing a sterilising solution comprising dissolving a composition of the first or second aspect in water at 40 0 C.
  • the method comprises dissolving between 10 and 3Og, most preferably between 18 and 22g, of the composition of the first or second aspect in 1 litre of water at 40 °C.
  • the method further comprises allowing the temperature of the solution to fall to room temperature once dissolution is complete.
  • dissolution is complete after 10 minutes, more preferably after 5 minutes .
  • an aqueous sterilising solution comprising:
  • amphoteric surfactant - 0.04 to 0.05 wt% amphoteric surfactant.
  • a method of sterilising medical equipment comprising the steps of :
  • the appropriate period is the time necessary to inhibit or kill a significant portion of the microbes present on the medical equipment .
  • the appropriate period is at least 1 minute, more preferably at least 2 minutes, more preferably at least 3 minutes, most preferably at least 5 minutes.
  • the appropriate period is less than 4 hours, more preferably less than 3, more preferably less than 2 hours, most preferably less than 1 hour.
  • At least 4.5 loglO of microbes present on the medical equipment prior to sterilisation are inhibited or destroyed, more preferably at least 5 loglO, more preferably at least 5.5 loglO, more preferably at least 6 loglO, most preferably at least 7 loglO.
  • composition of the present invention is active after the appropriate period, for example 5 minutes, against one or more of, and preferably all of, the following spores: Bacillus subtilis var niger and the following bacteria: Escheria coli, Mycobacterium tuberculosis, Staphylococcus aureus, Salmonella typhimurium, Pseudomonas aeruginosa, Campylobacter jejuni, Klebsiella aerogenes, Enterococcus faecium, Bacillus stearothermopohilus, Bacillus coagulans .
  • Bacillus subtilis var niger and the following bacteria: Escheria coli, Mycobacterium tuberculosis, Staphylococcus aureus, Salmonella typhimurium, Pseudomonas aeruginosa, Campylobacter jejuni, Klebsiella aerogenes, Enterococcus faecium, Bac
  • the composition of the present invention is active after the appropriate period, for example 5 minutes, against one or more of, and preferably all of, the following viruses: HIV, Adenovirus, Hepatitis B, Hepatitis C, Poliovirus, Cocksackievirus, Echovirus, Herpes simplex, Rotavirus.
  • viruses HIV, Adenovirus, Hepatitis B, Hepatitis C, Poliovirus, Cocksackievirus, Echovirus, Herpes simplex, Rotavirus.
  • the composition of the present invention is active after the appropriate period, for example 5 minutes, against one or more of, and preferably both of, the following Fungi: Candida albicans, Aspergillus niger (spores) .
  • the sterilising method of the fifth aspect of the present invention may be carried out at room temperature .
  • the sterilising solution is prepared from the composition of the first or second aspect immediately prior to use.
  • the composition may continue to be suitable for use for a period of at least 4 hours, more preferably at least 6 hours, more preferably at least 8 hours, most preferably at least 10 hours.
  • the composition will no longer be sufficiently active against microbes, there is a colour change of the sterilising solution.
  • a composition was prepared having the following components :
  • Nansa HS80/S linear alkylbenzene sulphonate
  • Beta-alanine,N- (carboxyethyl) -N-dodecyl monosodium salt (AMA 100)
  • Figure 1 shows a graph of the average peracetic acid release over the first 24 hours.
  • HIRL Hospital Infection Research Laboratory
  • University of Birmingham, UK found a reduction in colony forming units of > 6.5 loglO for Bacillus subtilis var niger spores in less than 2 minutes under clean and dirty conditions and a reduction of >5 loglO (5-8 loglO) c.f.u. for Mycobacterium tuberculosis in a clean and dirty carrier test with a contact time of 5 minutes .

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La présente invention a pour objet une préparation stérilisante qui comprend une source d'acide peracétique, au moins un tensioactif anionique et au moins un tensioactif amphotère. La présente invention a également pour objet une méthode d'utilisation de la préparation pour la stérilisation d'équipement médical.
PCT/GB2006/002165 2005-11-07 2006-06-14 Préparation et méthode WO2007051957A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06744206A EP1945274A1 (fr) 2005-11-07 2006-06-14 Préparation et méthode

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0522655.0 2005-11-07
GBGB0522655.0A GB0522655D0 (en) 2005-11-07 2005-11-07 Composition and method

Publications (1)

Publication Number Publication Date
WO2007051957A1 true WO2007051957A1 (fr) 2007-05-10

Family

ID=35516457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/002165 WO2007051957A1 (fr) 2005-11-07 2006-06-14 Préparation et méthode

Country Status (3)

Country Link
EP (1) EP1945274A1 (fr)
GB (1) GB0522655D0 (fr)
WO (1) WO2007051957A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080225A2 (fr) * 2007-12-21 2009-07-02 Cognis Ip Management Gmbh Adjuvants pour des applications agrochimiques
WO2011161396A3 (fr) * 2010-06-21 2012-02-16 Mtp Innovations Composition désinfectante
WO2014089633A1 (fr) 2012-12-14 2014-06-19 Saban Ventures Pty Limited Désinfectant
WO2014089632A1 (fr) * 2012-12-14 2014-06-19 Saban Ventures Pty Limited Renforcement synergétique de désinfection
WO2019034747A1 (fr) * 2017-08-16 2019-02-21 Ceva Sante Animale Nouveau désinfectant pour couvoirs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU720783B2 (en) * 1996-12-11 2000-06-15 Henkel-Ecolab Gmbh & Co. Ohg Process for disinfecting instruments
WO2000057703A1 (fr) * 1999-03-26 2000-10-05 Ecolab Inc. Compositions antimicrobiennes et antivirales contenant une espece oxydante
EP1064845A1 (fr) * 1999-06-30 2001-01-03 Kao Corporation Composition virucide et sporicide
EP1275401A1 (fr) * 2001-07-10 2003-01-15 Laboratoires Rivadis Composition à base de composé peroxyde et de composé N-acyle et procédé de désinfection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU720783B2 (en) * 1996-12-11 2000-06-15 Henkel-Ecolab Gmbh & Co. Ohg Process for disinfecting instruments
WO2000057703A1 (fr) * 1999-03-26 2000-10-05 Ecolab Inc. Compositions antimicrobiennes et antivirales contenant une espece oxydante
EP1064845A1 (fr) * 1999-06-30 2001-01-03 Kao Corporation Composition virucide et sporicide
EP1275401A1 (fr) * 2001-07-10 2003-01-15 Laboratoires Rivadis Composition à base de composé peroxyde et de composé N-acyle et procédé de désinfection

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080225A3 (fr) * 2007-12-21 2010-06-17 Cognis Ip Management Gmbh Adjuvants pour des applications agrochimiques
WO2009080225A2 (fr) * 2007-12-21 2009-07-02 Cognis Ip Management Gmbh Adjuvants pour des applications agrochimiques
AU2011268749B2 (en) * 2010-06-21 2014-08-07 Mtp Innovations Disinfectant composition
WO2011161396A3 (fr) * 2010-06-21 2012-02-16 Mtp Innovations Composition désinfectante
US10827752B2 (en) 2010-06-21 2020-11-10 Peter Finan Disinfectant composition
AU2013359956B2 (en) * 2012-12-14 2017-08-10 Saban Ventures Pty Limited Disinfectant
US9872930B2 (en) 2012-12-14 2018-01-23 Saban Ventures Pty Limited Synergistic disinfection enhancement
JP2016505564A (ja) * 2012-12-14 2016-02-25 サバン ベンチャーズ ピーティーワイ リミテッド 相乗的消毒作用増強
EP2934120A4 (fr) * 2012-12-14 2016-08-17 Saban Ventures Pty Ltd Renforcement synergétique de désinfection
AU2013359955B2 (en) * 2012-12-14 2017-08-10 Saban Ventures Pty Limited Synergistic disinfection enhancement
WO2014089632A1 (fr) * 2012-12-14 2014-06-19 Saban Ventures Pty Limited Renforcement synergétique de désinfection
US9789216B2 (en) 2012-12-14 2017-10-17 Saban Ventures Pty Limited Synergistic disinfection enhancement
CN104981156A (zh) * 2012-12-14 2015-10-14 萨班企业私人有限公司 协同消毒增强
US10206404B2 (en) 2012-12-14 2019-02-19 Saban Ventures Pty Limited Disinfectant
WO2014089633A1 (fr) 2012-12-14 2014-06-19 Saban Ventures Pty Limited Désinfectant
CN111065273A (zh) * 2017-08-16 2020-04-24 法国诗华大药厂 用于孵化场的新消毒剂
KR20200085726A (ko) * 2017-08-16 2020-07-15 세바 상뜨 아니말르 부화장용 신규 소독제
WO2019034747A1 (fr) * 2017-08-16 2019-02-21 Ceva Sante Animale Nouveau désinfectant pour couvoirs
KR102630888B1 (ko) 2017-08-16 2024-01-29 세바 상뜨 아니말르 부화장용 신규 소독제
US11917998B2 (en) 2017-08-16 2024-03-05 Ceva Sante Animale Disinfectant for hatcheries

Also Published As

Publication number Publication date
GB0522655D0 (en) 2005-12-14
EP1945274A1 (fr) 2008-07-23

Similar Documents

Publication Publication Date Title
EP0953283B9 (fr) Procédé pour la production sur place d'un système désinfectant de l'acide péracétique
US7235252B2 (en) Method of preparing organic peroxyacids
US9233180B2 (en) Hydrogen peroxide disinfectant containing a cyclic carboxylic acid and/or aromatic alcohol
CA2733644C (fr) Solutions desinfectantes concentrees de peroxyde d'hydrogene
EP1945274A1 (fr) Préparation et méthode
CZ175695A3 (en) Composition and the use thereof
EP2326704A2 (fr) Composition désinfectante et de nettoyage granulaire
JPH06501913A (ja) 防食性殺菌剤
JPH09500630A (ja) 延長された活性寿命を有する冷滅菌剤
JP2002532398A (ja) 高活性を有する過酸化水素系消毒薬
CA2126729C (fr) Composition a base de peroxyde d'hydrogene
JP2001505896A (ja) 器具を消毒するための方法
WO2012010198A1 (fr) Composition multicomposant solide pour nettoyage et désinfection
US11076598B2 (en) Peroxide-based disinfecting solutions containing inorganic salts
JP5500835B2 (ja) 除菌・抗菌剤組成物
WO2021161148A1 (fr) Compositions antimicrobiennes contenant de l'acide peroxyphthalique et/ou un sel de celui-ci
EP0096525B1 (fr) Compositions contenant un agent assainissant
JP2010095448A (ja) 医療器具用消毒液及び医療器具消毒方法
WO2011040201A1 (fr) Détergent pour prothèse dentaire
CN111387189A (zh) 一种消毒剂组合物
RU2217170C2 (ru) Дезинфицирующее средство
BR112021009126A2 (pt) composições antimicrobianas contendo c3-c6 n-alquilgama- butirolactama e peroxigênio
JP5641759B2 (ja) 義歯洗浄剤
CA3000262A1 (fr) Compositions antimicrobiennes a base d'ether de glycerol
RU2371917C1 (ru) Дезинфицирующая композиция

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006744206

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2006744206

Country of ref document: EP